Scientific evidence and financial obligations to ensure access to biosimilars for cancer treatment
Mené sur 500 patientes atteintes d'un cancer du sein HER2+ métastique, cet essai de phase III compare l'efficacité, du point de vue du taux de réponse globale à 24 semaines, et la toxicité du trastuzumab et d'un médicament biosimilaire, en complément d'une chimiothérapie à base de taxanes
In this issue of JAMA, Rugo and colleagues1 report findings from a multicenter clinical trial that may influence care for patients with breast cancer around the world. The authors evaluated the equivalence of a proposed trastuzumab biosimilar compared with the standard therapy, the humanized monoclonal antibody trastuzumab, for achieving overall response and for safety among 458 women without prior treatment for ERBB2 (HER2)–positive metastatic breast cancer.
JAMA , éditorial, 2015